Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) is projected to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Cabaletta Bio to post earnings of ($0.4579) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.

Cabaletta Bio Stock Up 5.5%

NASDAQ CABA opened at $3.43 on Thursday. The stock has a market cap of $330.17 million, a PE ratio of -1.36 and a beta of 3.25. Cabaletta Bio has a fifty-two week low of $0.99 and a fifty-two week high of $3.78. The business has a 50 day moving average price of $2.62 and a two-hundred day moving average price of $2.39.

Insider Buying and Selling

In related news, insider Steve Gavel acquired 22,170 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The shares were acquired at an average cost of $2.27 per share, with a total value of $50,325.90. Following the purchase, the insider owned 22,170 shares of the company’s stock, valued at approximately $50,325.90. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Nichtberger bought 45,000 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The stock was bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the completion of the acquisition, the chief executive officer owned 1,031,483 shares in the company, valued at approximately $2,310,521.92. The trade was a 4.56% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 127,668 shares of company stock valued at $286,211 in the last three months. 11.25% of the stock is currently owned by corporate insiders.

Institutional Trading of Cabaletta Bio

Hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. lifted its position in Cabaletta Bio by 17.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company’s stock worth $21,590,000 after purchasing an additional 1,495,768 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Cabaletta Bio by 142.9% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock valued at $13,421,000 after buying an additional 5,195,285 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Cabaletta Bio by 21.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company’s stock worth $9,806,000 after acquiring an additional 740,032 shares during the period. Millennium Management LLC boosted its position in shares of Cabaletta Bio by 298.5% during the 4th quarter. Millennium Management LLC now owns 2,736,912 shares of the company’s stock valued at $5,994,000 after acquiring an additional 2,050,099 shares in the last quarter. Finally, Superstring Capital Management LP boosted its position in shares of Cabaletta Bio by 45.9% during the 4th quarter. Superstring Capital Management LP now owns 2,253,550 shares of the company’s stock valued at $4,935,000 after acquiring an additional 709,025 shares in the last quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cabaletta Bio has an average rating of “Moderate Buy” and a consensus price target of $16.25.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.